-
Sector Analysis
NewAutomotive Autonomous Driving Systems Market Trends, Sector Overview and Forecast to 2028
The size of the global autonomous driving systems market was 212.5 mn units in 2023, recording a substantial annual growth of 15.2%. During 2018–23, the sector posted a CAGR of 5.1%. Over the forecast period, the sector is expected to record a CAGR of 5.2% to reach 274.2 mn units by 2028. In 2023 adaptive cruise control (ACC) garnered a share of 14.0%, radar -–long range garnered a share of 16.3%, radar-short/medium garnered a share of 27.7%, and GPS/GNSS unit...
-
Product Insights
NewClot Management Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Clot Management Devices Pipeline Market Report Overview Clot Management Devices are used for the removal or dissolution of a clot from a blood vessel to restore proper blood circulation. This device is used as a routine procedure while performing percutaneous coronary intervention and for treating potentially life-threatening complications. The clot management devices pipeline market research report provides comprehensive information on the products with their comparative segment-wise analysis in various stages of development. The report also covers the regional and country-wise...
-
Product Insights
NewImage Guided Surgery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Image Guided Surgery Pipeline Market Report Overview Image Guided Surgery devices use real-time images during surgery to assist surgeons in precisely guiding the surgical instruments to the anatomic structures. It helps minimize the chances of errors and reduce the procedure time. The Image Guided Surgery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-521 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-521 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AB-521 in Solid Tumor Drug Details: AB-521 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-521 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-521 in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AB-521 in Renal Cell Carcinoma Drug Details: AB-521 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Metastatic Melanoma Drug Details: RP-1 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Nelfinavir Mesylate in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nelfinavir Mesylate in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nelfinavir Mesylate in Multiple Myeloma (Kahler Disease) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Round Cell Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Round Cell Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Round Cell Liposarcoma Drug Details: Eftilagimod...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Melanoma Drug Details: RP-1 is under development for the...